Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is -17.71% lower on its value in year-to-date trading and has touched a low of $14.23 and a high of $30.41 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARWR stock was last observed hovering at around $15.10 in the last trading session, with the day’s gains setting it 0.37%.
Currently trading at $15.47, the stock is -10.52% and -17.46% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.27 million and changing 2.48% at the moment leaves the stock -29.05% off its SMA200. ARWR registered -45.30% loss for a year compared to 6-month loss of -24.35%. The firm has a 50-day simple moving average (SMA 50) of $18.7425 and a 200-day simple moving average (SMA200) of $21.80275.
The stock witnessed a -24.32% gain in the last 1 month and extending the period to 3 months gives it a -29.20%, and is -1.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.63% over the week and 5.99% over the month.
Arrowhead Pharmaceuticals Inc (ARWR) has around 609 employees, a market worth around $2.12B and $2.50M in sales. Profit margin for the company is -25588.56%. Distance from 52-week low is 8.75% and -49.13% from its 52-week high. The company has generated returns on investments over the last 12 months (-69.80%).
with sales reaching $118.54M over the same period.The EPS is expected to grow by 43.28% this year, but quarterly earnings will post 8,478.60% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
364.0 institutions hold shares in Arrowhead Pharmaceuticals Inc (ARWR), with institutional investors hold 85.93% of the company’s shares. The shares outstanding are 125.57M, and float is at 114.47M with Short Float at 8.03%. Institutions hold 74.59% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.68 million shares valued at $$407.61 million. The investor’s holdings represent 12.7211 of the ARWR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.21 million shares valued at $$317.44 million to account for 9.9072 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 8.89 million shares representing 7.157 and valued at over $$231.02 million, while FMR LLC holds 5.4849 of the shares totaling 6.81 million with a market value of $$177.05 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
The most recent transaction is an insider sale by Anzalone Christopher Richard, the company’s Chief Executive Officer. SEC filings show that Anzalone Christopher Richard sold 51,425 shares of the company’s common stock on Mar 13 ’25 at a price of $15.07 per share for a total of $0.77 million. Following the sale, the insider now owns 4.06 million shares.
Still, SEC filings show that on Mar 03 ’25, Anzalone Christopher Richard (Chief Executive Officer) disposed off 166,667 shares at an average price of $18.03 for $3.01 million. The insider now directly holds 3,907,135 shares of Arrowhead Pharmaceuticals Inc (ARWR).
